Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33982-33992

  Del Prete, Michela ^a   Giampieri, Riccardo ^a   Loupakis, Fotios ^c   Prochilo, Tiziana ^b   Salvatore, Lisa ^c   Faloppi, Luca ^a   Bianconi, Maristella ^a   Bittoni, Alessandro ^a   Aprile, Giuseppe ^d   Zaniboni, Alberto ^b   Falcone, Alfredo ^c   Scartozzi, Mario ^e   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b Medical Oncology   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^e DEPARTMENT OF RADIOLOGY   (Italy)

Author keywords

Colorectal cancer; LDH; Neutrophil lymphocyte ratio; Prognostic factors; Regorafenib

Indexed keywords

LACTATE DEHYDROGENASE; REGORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MONOTHERAPY; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; BLOOD; COLORECTAL NEOPLASMS; CYTOLOGY; DRUG EFFECTS; INFLAMMATION; KAPLAN MEIER METHOD; LYMPHOCYTE; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOVASCULARIZATION (PATHOLOGY); NEUTROPHIL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHILS; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; RETROSPECTIVE STUDIES; ROC CURVE; TREATMENT OUTCOME;

EID: 84946083938     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5053     Document Type: Article

References (36)

1. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381:303-12.
2. Maxwell PH, Pugh CW, Ratcliffe PJ. Activation of the HIF pathway in cancer. Curr Opin Genet Dev. 2001; 11:293-9.
3. Koukourakis MI, Giatromanolaki A, Sivridis E. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol. 2003; 24:199-202.
4. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2:38-47.
5. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007; 8:1705-1713.
6. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001; 24:547-50.
7. Tas F, Aydiner A, Demir C, Topuz E. Lactate dehydrogenase levels at presentation predict outcome of patients with limited stage small-cell lung cancer. Am J Clin Oncol. 2001; 24:376-8.
8. Koukourakis MI, Giatromanolaki A, Simopoulos C, Polychronidis A, Sivridis E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin Exp Metastasis. 2005; 22:25-30.
9. Wu XZ, Ma F, Wang XL. Serological diagnostic factors for liver metastasis in patients with colorectal cancer. World J Gastroenterol. 2010; 16:4084-4088.
10. Hecht JR, Trarbach T, Hainsworth JD, Major P, Jäger E, WolffRA, Lloyd-Salvant K, Bodoky G, Pendergrass K, Berg W, Chen BL, Jalava T, Meinhardt G, Laurent D, Lebwohl D, Kerr D. Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. J Clin Oncol. 2011; May;20;29:1997-2003.
11. Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lebwohl D, Meinhardt G, Laurent D, Lin E. Randomized, placebo-controlled, phase III study of Oxaliplatin, Fluorouracil and Leucovorin with or without PTK787/ZK222584 in patients with previously treated metastatic colorectal adenocarcinoma. J Clin Oncol. 2011; May 20;29:2004-2010.
12. Koukourakis MI, Giatromanolaki A, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL. Prognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy. Clin Cancer Res. 2011; Jul 15;17:4892-4900.
13. Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S. Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. Br J Cancer. 2012; 106:799-804.
14. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009; Jul 30:1073-1081.
15. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
16. Mantovani A, Allavena P, Sica A, Balkwill F. Cancerrelated inflammation. Nature. 2008; 454:436-444.
17. Proctor MJ, McMillan DC, Morrison DS, Fletcher CD, Horgan PG, Clarke SJ. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012; 107:695-699.
18. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005; 91:181-184.
19. Paramanathan A, Saxena A, Morris DL. A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours. Surg Oncol. 2014; 23:31-39.
20. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Combination of platelet count and neutrophil to lymphocite ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br J Cancer. 2013; Jul 23;109:401-7. doi:10.1038/bjc.2013.350. Epub 2013 Jul 2.
21. Absenger G, Szkandera J, Stotz M, Postlmayr U, Pichler M, Ress AL, Schaberl-Moser R, Loibner H, Samonigg H, Gerger A. Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. Anticancer Res. 2013; 33:4591-4.
22. Absenger G, Szkandera J, Pichler M, Stotz M, Arminger F, Weissmueller M, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A. A derived neutrophil to lymphocyte ratio predicts clinical outcome in stage II and III colon cancer patients. Br J Cancer. 2013; 109:395-400. doi: 10.1038/bjc.2013.346. Epub 2013 Jul 2.
23. Li MX, Liu XM, Zhang XF, Zhang JF, Wang WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L, Lv Y. Prognostic role of neutophil to lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2014; May 15; 134:2403-13. doi: 10.1002/ijc.28536. Epub 2014 Jan 29.
24. Milasiene V, Stratilatovas E, Norkiene V, Jonusauskaite R. Lymphocyte subsets in peripheral blood as prognostic factors in colorectal cancer. J Buon. 2005; 10:261-4.
25. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas. 2006; 32:22-8.
26. Saroha S, Uzzo RG, Plimack ER, Ruth K, Al-Saleem T. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol. 2013; 189:454-61.
27. Lissoni P, Fumagalli L, Brivio F, Rovelli F, Messina G, Di Fede G, Colciago M, Brera G. Cancer chemotherapyinduced lymphocytosis: a revolutionary discovery in the medical oncology. J Biol Regul Homeost Agents. 2006; 20:29-35.
28. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil to lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009; 16:614-622.
29. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011; 104:1288-1295.
30. Guillem-Llobat P, Dovizio M, Alberti S, Bruno A, Patrignani P. Platelets, cyclooxygenases, and colon cancer. Semin Oncol. 2014; 41:385-96.
31. Clarke S, Burge M, Cordwell C, Gibbs P, Reece W, Tebbutt N. An australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin)[ASCENT]. BMC Cancer. 2013; 13:120.
32. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011; Nov 47:2633-41. doi: 10.1016/j.ejca.2011.03.028. Epub 2011 Jul 1.
33. Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003; 6:283-287.
34. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011; Jul 12:642-53. doi: 10.1016/S1470-2045(11)70102-4. Epub 2011 Jun 5.
35. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21:137-148.
36. Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A. Functional analysis of mononuclear cells infiltrating into tumours: lysis of autologous human tumour cells by cultured infiltrating lymphocytes. Cancer Res. 1987; 47:173-177.